Carlos García Girón-rekin lankidetzan egindako argitalpenak (8)

2021

  1. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

1996

  1. Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen

    Cancer Chemotherapy and Pharmacology, Vol. 38, Núm. 2, pp. 191-194

  2. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin: A phase II study of the ONCOPAZ Cooperative Group

    Cancer, Vol. 78, Núm. 2, pp. 211-216

1995

  1. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study

    European Journal of Cancer, Vol. 31, Núm. 13-14, pp. 2215-2219

  2. Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ cooperative group

    Cancer Chemotherapy and Pharmacology, Vol. 36, Núm. 3, pp. 255-258

1994

  1. FLEP (5-fluorouracil, leucovorin, etoposide, cisplatin) in advanced gastric cancer

    European Journal of Cancer, Vol. 30, Núm. 11, pp. 1733-1734

1990

  1. Phase II trial of cisplatin and tegafur (Ftorafur) as initial therapy in squamous-cell carcinoma of the head and neck

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 13, Núm. 4, pp. 312-314

1989

  1. Control de adenocarcinoma suprarrenal y síndrome de Cushing con cetoconazol.

    Medicina Clinica